---
document_datetime: 2023-09-21 21:48:15
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/terrosa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: terrosa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.7016772
conversion_datetime: 2025-12-24 21:41:20.336735
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Terrosa

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0027/G            | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 03/02/2023                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | manufacturer of a novel excipient B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                   |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0026/G | This was an application for a group of variations. Please refer to the Recommendations section B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished | 10/11/2022 | SmPC, Labelling and PL | The SmPC sections 1, 2, 4.2, 6.4, 6.5 and 6.6 have been updated to reflect the addition of the new pre-filled pens presentations (EU/1/16/1159/004-005) or adapted to address the specific features of the pre-filled pen presentation. The Labelling and PL have been updated accordingly. The package leaflet contains a Pen user manual for the Terrosa 20 micrograms (Âµg)/80 microliters solution for injection, in pre-filled pen. |

<div style=\"page-break-after: always\"></div>

|                    | product - Addition of a new test(s) and limits B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.IV.1.c - Change of a measuring or administration device - Addition or replacement of a device which is an integrated part of the primary packaging   |            |            |                        |                                                                                                                                                                             |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2903/ 202109 | Periodic Safety Update EU Single assessment - teriparatide                                                                                                                                                                                                                                                                                                                                                                                    | 05/05/2022 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                           |
| IB/0024/G          | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                      | 13/12/2021 | n/a        |                        |                                                                                                                                                                             |
| IB/0023            | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                  | 02/12/2021 | n/a        |                        |                                                                                                                                                                             |
| R/0020             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                       | 22/07/2021 | 16/09/2021 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Terrosa in the approved indication remains favourable and |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                                  | therefore recommended the renewal of the marketing authorisation with unlimited validity. The RMP has been also updated (version 2.2).   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0021/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                         | 06/08/2021 | n/a        |                                  |                                                                                                                                          |
| IB/0019/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process | 07/01/2021 | n/a        |                                  |                                                                                                                                          |
| II/0018   | B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products                                                                                                                                                                                                           | 17/09/2020 | 16/09/2021 | SmPC, Annex II, Labelling and PL |                                                                                                                                          |
| IB/0016/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of                                                                                                                                                                                                                                                                                                 | 17/04/2020 | n/a        |                                  |                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | the AS - Minor change in the manufacturing process of the AS B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits   |            |            |                  |     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|-----|
| IAIN/0017 | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                     | 10/04/2020 | n/a        |                  |     |
| IB/0014   | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                              | 09/01/2020 | n/a        |                  |     |
| N/0013    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                        | 30/12/2019 | 09/03/2020 | Labelling and PL |     |
| IA/0012   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                          | 26/06/2019 | n/a        |                  |     |
| II/0009   | Submission of the final clinical study report from Study RGB1023O31; a Phase III, multi-centre, randomised, active-controlled, parallel-group, comparative efficacy/safety study. An updated RMP version 1.4 was agreed during the procedure.                           | 14/06/2019 | n/a        |                  | n/a |

<div style=\"page-break-after: always\"></div>

|                    | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                               |            |            |                        |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IA/0011            | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)            | 24/05/2019 | n/a        |                        |                                   |
| II/0010            | B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products                | 23/05/2019 | n/a        |                        |                                   |
| PSUSA/2903/ 201809 | Periodic Safety Update EU Single assessment - teriparatide                                                                                                                                                  | 16/05/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0006            | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                         | 26/03/2019 | 09/03/2020 | SmPC, Labelling and PL |                                   |
| IA/0007            | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                | 18/12/2018 | n/a        |                        |                                   |
| IB/0005/G          | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or | 30/10/2018 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|         | intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.z - Quality change - Active substance - Other variation B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material   |            |            |                       |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|
| IB/0004 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 23/02/2018 | 07/02/2019 | SmPC, Annex II and PL |
| IA/0003 | A.z - Administrative change - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 05/04/2017 | 05/03/2018 | SmPC, Labelling and   |

<div style=\"page-break-after: always\"></div>

| IB/0001/G   | This was an application for a group of variations.                                                                                                                                                                                                  | 05/04/2017   | n/a   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
|             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data |              |       |